1. Home » 
  2. Markets » 
  3. Syngene AGM to Approve Rs1.25 Dividend per 10 Rs Share

Syngene AGM to Approve Rs1.25 Dividend per 10 Rs Share

Syngene's AGM will approve a ₹1.25 dividend per ₹10 share, with a total payout of ₹503.17 million, scheduled for August 5, 2024.

by Damodharan N

Updated Jul 04, 2024

Article continues below advertisement
Syngene AGM to Approve Rs1.25 Dividend per 10 Rs Share

In the upcoming Annual General Meeting (AGM) of Syngene for Wednesday, July 24, 2024, at 3:30 pm IST. one of the key issues shareholders might look out far is divdined declaration The Board of Syngene International Limited has recommended a final dividend of ₹1.25 per share for FY24.

This will result in a total payout of ₹503.17 million, along with applicable taxes. If approved at the Annual General Meeting (AGM), the dividend will be paid to members listed in the Company’s Register of Members as of June 28, 2024. The payout date is set on or before August 5, 2024.

The AGM meeting will be held through Video Conferencing and Other Audio-Visual Means to also discuss the other key issues like 

  1. Adoption of Audited Financial Statements for FY 2023-24.
  2. Declaration of ₹1.25 dividend per ₹10 share for FY 2023-24.
  3. Re-appointment of Ms. Kiran Mazumdar Shaw as Director.
  4. Re-appointment of Dr. Kush Parmar as Independent Director.
  5. Appointment of Ms. Manja Boerman as Independent Director.

Syngene Annual Report 

Syngene International Limited has achieved remarkable milestones in FY 2024, showcasing robust financial performance and strategic advancements across its business verticals. The company's consolidated revenue surged by 20% year-on-year, reaching INR 35,000 million, while standalone revenue stood strong at INR 30,000 million.

This growth was driven by significant contributions from its core segments: Discovery Services, Development and Manufacturing Services, and Dedicated R&D Centers.

Management's analysis highlights key strengths, including Syngene's state-of-the-art infrastructure, strategic collaborations with global pharma giants, and a commitment to digital transformation.

The company launched multiple initiatives such as the adoption of Electronic Lab Notebooks (ELNs) and the implementation of a Material Requirement Planning (MRP) system to enhance operational efficiency and compliance.

However, Syngene also faced challenges, notably in managing supply chain disruptions and regulatory hurdles. Despite these obstacles, the future outlook remains optimistic, with plans to expand capabilities in biologics, small molecules, and advanced therapeutic platforms.

Key projects completed include the commissioning of a centralized compound management facility in Hyderabad and the launch of the Induced Pluripotent Stem Cells (iPSCs) platform.

Looking ahead, Syngene is poised for continued growth, leveraging its technological prowess and strategic partnerships to drive innovation and deliver value to stakeholders.

Key Financial Metrics:

The company's key financial metrics that shareholders and investors should look out for are given below 

  • Consolidated Revenue: INR 35,000 million
  • Standalone Revenue: INR 30,000 million
  • Revenue: Increased by 0.82% to ₹32,911 million.
  • EBITDA: Decreased by 3.82% to ₹9,668 million.
  • Profit After Tax: Decreased by 1.39% to ₹4,665 million.

Standalone Performance (FY24 vs. FY23)

Particulars

March 31, 2024

March 31, 2023

Change (%)

Total Revenue (Rs. in Million)

32,911

32,644

+0.82%

Total Expenditure (Rs. in Million)

27,227

26,635

+2.22%

Profit before Depreciation, Finance Costs, etc. (Rs. in Million)

9,668

10,052

-3.82%

Depreciation & Interest (Rs. in Million)

3,984

4,043

-1.46%

Profit before Exceptional Items and Tax (Rs. in Million)

5,684

6,009

-5.41%

Exceptional Items (Rs. in Million)

(111)

-

-

Profit before Tax Expense (Rs. in Million)

5,573

6,009

-7.26%

Tax Expenses (Rs. in Million)

908

1,279

-29.00%

Profit for the Year (Rs. in Million)

4,665

4,730

-1.37%

Other Comprehensive Income (Rs. in Million)

1,431

(972)

-

Total Comprehensive Income (Rs. in Million)

6,096

3,758

+62.18%

Profit for the Year Excluding Exceptional Item (Rs. in Million)

4,776

4,730

+0.97%

FY24 Financial Performance (Consolidated)

Particulars

FY24

FY23

Change (%)

Revenue from operations

34,886

31,929

9%

Other income (refer note 1)

906

709

28%

Reported revenue

35,792

32,638

10%

Costs of chemicals, reagents, and consumables consumed

9,302

8,602

8%

Employee benefits expense

9,607

8,876

8%

Other expenses

5,275

4,689

13%

Foreign exchange fluctuation gain/(loss), net

(558)

(418)

34%

EBITDA

11,050

10,053

10%

Depreciation and amortisation expenses

4,259

3,665

16%

EBIT

6,791

6,388

6%

Finance costs

472

452

4%

PBT

6,319

5,936

6%

Tax (refer note 2)

1,133

1,292

-12%

PAT before exceptional item

5,186

4,644

12%

Exceptional item (refer note 3)

86

0

N/a

PAT after exceptional item

5,100

4,644

10%

Normalized PAT (refer note 4)

4,827

4,644

4%

Other comprehensive income for the year

1,426

(972)

N/a

Total comprehensive income for the year

6,526

3,672

78%

Notes:

  • Interest income of ₹158 million from an income tax refund for FY 2009-10 and FY 2010-11 is included under "Other Income".
  • Reversal of income tax provision amounting to ₹232 million due to favorable tax assessment orders.
  • Exceptional item in FY24 pertains to transaction costs related to the acquisition of the multi-modal facility from Stelis Biopharma Limited.
  • Normalized PAT for FY24 adjusts for interest income (net of tax ₹127 million) and the reversal of income tax provision of ₹232 million.

Operational Review:

Syngene is an integrated research, development, and manufacturing services company serving global pharmaceutical, biotechnology, and other sectors. With over 5600 scientists, Syngene offers robust data security and quality manufacturing, accelerating time-to-market and reducing innovation costs.

Discovery Services:

Syngene's Discovery Services offers comprehensive research and development solutions to global pharmaceutical, biotechnology, and other industries. The company focuses on accelerating innovation with its advanced scientific capabilities and state-of-the-art facilities.

  • Impacted by the US biotech funding slowdown, but signs of stabilization are emerging.
  • Purchased 17-acre land in Genome Valley, Hyderabad, to expand research operations, with new facilities planned for FY25.
  • Added biologics assay capability at Hyderabad campus.

Development Services:

Syngene International Ltd., a leading contract research organization, specializes in providing integrated discovery and development services in the last financial year Commissioned a non-GMP facility in Bangalore for early-phase development projects.

Manufacturing Services:

The Company has done also well in building up its capability of the manufacturing its capacity in the past year. Some of them are listed below 

  • Acquired biologics manufacturing facility from Stelis Biopharma Ltd., expected to be operational in the second half of FY25.
  • Progressed on a 10-year biologics manufacturing agreement with Zoetis.
  • Commissioned a state-of-the-art Quality Control laboratory.
  • Mangalore facility received US FDA approval and ISO: 50001 certification.

Dedicated R&D Centers:

The company also operates the Key R&D sectors that focus on improving its knowledge capacity. 

  • Operates centers for Amgen, Baxter, and Bristol-Myers Squibb, reporting steady performance. Key initiative that happened are 
  • Digital transformation through ELNs and MRP system
  • Expansion of biologics and small molecule platforms

Projects Completed:

In the last financial year company completed the key projects which are listed below. 

  • Centralized compound management facility in Hyderabad
  • Launch of iPSCs platform

Future Outlook:

The Syngene annual report has highlighted the key things to look out for in the upcoming year which are given below. 

  • Expansion in biologics and advanced therapeutic platforms
  • Strengthening global strategic partnerships

Syngene's FY 2024 performance underscores its resilience and strategic vision, setting a strong foundation for future growth and innovation.

Read the full Notice and Annual Report Here  

Article continues below advertisement
Article continues below advertisement

Syngene 

Syngene International Ltd., established in 1993 and publicly listed in India, is a leading contract research, development, and manufacturing organization (CRDMO). It serves diverse sectors including pharmaceuticals, biotechnology, animal healthcare, consumer goods, and agrochemicals.

Syngene collaborates with global leaders, startups, academic institutions, and government bodies, leveraging a team of over 6000 scientists and specialized platforms like SynVent for drug discovery and development.

The company emphasizes innovation, efficiency, and sustainability, with a strong focus on corporate governance and ESG principles. Their integrated services and global supply chain ensure seamless support to clients worldwide, facilitating rapid market access and patient benefit.


Syngene AGM to Approve Rs 1.25 Dividend per 10 Rs Share - FAQs

1. What was Syngene's consolidated revenue in FY 2024?      

Syngene's consolidated revenue in FY 2024 is INR 35,000 million.

2. What was Syngene's standalone revenue in FY 2024?  

Syngene's standalone revenue in FY 2024 is INR 30,000 million.

3. How did Syngene's revenue change year-on-year?  

Syngene's revenue change year-on-year increased by 20%.

4. What was the total revenue reported for FY 2024?  

The total revenue reported for FY 2024 is ₹35,792 million.

5. How much did Syngene's standalone revenue increase in FY 2024?  

Syngene's standalone revenue increase in FY 2024 is increased by 0.82% to ₹32,911 million.

6. What was Syngene's EBITDA in FY 2024?  

Syngene's EBITDA in FY 2024 is ₹11,050 million.

7. How did Syngene’s EBITDA change compared to FY 2023?  

Syngene’s EBITDA change Increased by 10% compared to FY 2023

8. What was Syngene's Profit After Tax (PAT) for FY 2024?  

Syngene's Profit After Tax (PAT) for FY 2024 is ₹4,665 million.

9. How did the PAT change from FY 2023?  

The PAT change Decreased by 1.37% from FY 2023

10. What was the Profit Before Tax (PBT) in FY 2024?  

The Profit Before Tax (PBT) in FY 2024 is ₹6,319 million.

11. How did Syngene’s PBT change compared to FY 2023?      

Syngene’s PBT change increased by 6% compared to FY 2023

12. What were the tax expenses for FY 2024?  

The tax expenses for FY 2024 is ₹1,133 million.

13. How did tax expenses in FY 2024 compare to FY 2023?  

The tax expenses in FY 2024 Decreased by 12% compare to FY 2023

14. What was the total comprehensive income for FY 2024?  

The total comprehensive income for FY 2024 is ₹6,526 million.

15. How did the total comprehensive income change from FY 2023?      

The total comprehensive income Increased by 78% change from FY 2023

16. What was the revenue from operations in FY 2024?  

The revenue from operations in FY 2024 is ₹34,886 million.

17. How much other income did Syngene report in FY 2024?  

The other income Syngene reported in FY 2024 is ₹906 million.

18. What were the costs of chemicals and consumables consumed in FY 2024?  

The costs of chemicals and consumables consumed in FY 2024 is ₹9,302 million.

19. How did employee benefits expense change in FY 2024?  

The employee benefits expense Increased by 8% to ₹9,607 million in FY 2024

20. What were Syngene's other expenses in FY 2024?  

Syngene's other expenses in FY 2024 is ₹5,275 million.

21. What was the foreign exchange fluctuation loss in FY 2024?      

The foreign exchange fluctuation loss in FY 2024 is ₹558 million.

22. How much did Syngene’s depreciation and amortization expenses increase in FY 2024?  

Syngene’s depreciation and amortization expenses increase in FY 2024 is Increased by 16% to ₹4,259 million.

23. What was Syngene's EBIT in FY 2024?  

Syngene's EBIT in FY 2024 is ₹6,791 million.

24. How did Syngene’s finance costs change in FY 2024?  

Syngene’s finance costs Increased by 4% to ₹472 million in FY 2024

25. What was Syngene's Profit Before Depreciation, Finance Costs, etc. in FY 2024?  

Syngene's Profit Before Depreciation, Finance Costs in FY 2024 is ₹9,668 million.

26. How did the profit before exceptional items and tax change in FY 2024?  

The profit before exceptional items and tax change in FY 2024 is Decreased by 5.41% to ₹5,684 million.

27. What was the exceptional item reported in FY 2024?      

The exceptional item reported in FY 2024 is ₹86 million related to acquisition costs.

28. What was Syngene's normalized PAT in FY 2024?  

Syngene's normalized PAT in FY 2024 is ₹4,827 million.

29. How did the normalized PAT compare to FY 2023?  

The normalized PAT Increased by 4% compare to FY 2023

30. What was the profit for the year excluding exceptional items in FY 2024?  

The profit for the year excluding exceptional items in FY 2024 is ₹4,776 million.

31. What was Syngene's total expenditure in FY 2024?  

Syngene's total expenditure in FY 2024 is ₹27,227 million.

32. How did total expenditure change compared to FY 2023?  

The total expenditure Increased by 2.22% change compared to FY 2023

33. What was the revenue growth rate for FY 2024?      

The revenue growth rate for FY 2024 is 10%.

34. How much did Syngene's employee benefits expense increase by FY 2024?  

Syngene's employee benefits expense increased by 8% to ₹9,607 million by FY 2024

35. What was Syngene's depreciation and interest expense in FY 2024?      

Syngene's depreciation and interest expense in FY 2024 is ₹3,984 million.

36. What was the revenue from operations for FY 2023?  

The revenue from operations for FY 2023 is ₹31,929 million.

37. How did Syngene's profit before tax expense change in FY 2024?  

Syngene's profit before tax expense change in FY 2024 is Decreased by 7.26% to ₹5,573 million.

38. What was the other comprehensive income for FY 2024?    

The other comprehensive income for FY 2024 is ₹1,431 million.

39. How did other comprehensive income change from FY 2023?  

The other comprehensive income Increased from a loss of ₹972 million.

40. What was the total revenue reported for FY 2023?  

The total revenue reported for FY 2023 is ₹32,638 million.

Disclaimer : The above information is for general informational purposes only. All information on the Site is provided in good faith, however we make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability or completeness of any information on the Site.